Today: 21 May 2026
GE Aerospace stock closes higher after GE9X durability flag — what to watch next
30 January 2026
2 mins read

GE Aerospace stock closes higher after GE9X durability flag — what to watch next

New York, Jan 29, 2026, 21:29 EST — Market closed

  • Shares of GE Aerospace finished Thursday up 2.2%, closing at $298.86
  • Boeing has raised concerns about a possible durability problem with GE’s GE9X engine used on the 777-9
  • Investors are bracing for inspection updates and air show news set to drop next week as they head into Friday.

GE Aerospace shares rose 2.2%, finishing Thursday at $298.86, after closing Wednesday at $292.48. The stock has shown volatility recently, with traders balancing new technical developments against solid profits fueled by its services segment.

Jet engines have become the bottleneck in commercial aviation, with rising flight volumes, delayed aircraft deliveries, and limited repair capacity all piling up maintenance backlogs. Rick Deurloo, head of commercial engines at Pratt & Whitney, said the supply-demand mismatch should “level off by the end of the decade.” Still, he cautioned the supply chain remains a tough grind. Reuters

Boeing raised a fresh concern this week. CEO Kelly Ortberg told investors the company uncovered “a potential durability issue” during a recent check of the 777-9 engine. Boeing is collaborating with GE to finalize a solution, FlightGlobal reported. Flight Global

Boeing’s latest results highlighted why investors keep a close eye on its production pipeline. The aerospace giant posted a fourth-quarter profit, boosted by a unit sale, and signaled plans to ramp up output on major programs as it pushes through certifications like the 777X, according to a report.

In its regulatory filing for the year ended Dec. 31, 2025, GE reported an 18% jump in total revenue to $45.855 billion, with services accounting for $30.163 billion. Net income from continuing operations available to common shareholders reached $8.601 billion. Free cash flow — the cash remaining after capital expenditures and other exclusions — hit $7.694 billion. The company’s remaining performance obligation, representing contracted work not yet recognized as revenue, was $190.564 billion. GE also revealed it bought back 29.6 million shares for $7.4 billion last year, with approximately $2.698 billion still available under its buyback authorization.

Aerospace suppliers saw a generally positive signal on demand. Honeywell reported its aerospace unit’s sales climbed 13.4% to $4.52 billion in the fourth quarter, driven by robust aftermarket activity, Reuters said.

Durability concerns can quickly turn costly. Should the GE9X inspection expand or reveal the need for a major redesign, investors will factor in bigger expenses, delayed deliveries, and tighter cash flow — and the stock won’t hang around for a clear resolution.

Friday’s session hinges on one key thing: fresh updates from Boeing or GE about the root cause and how deep the issue goes. If those don’t come, traders will fall back on the usual signals — moves from other aerospace stocks, macroeconomic data, and whether buyers stick around after Thursday’s rebound.

Next week sets the scene for deals and headlines. GE is scheduled to appear at the Singapore Airshow from Feb. 3-8, a hotspot where engine makers and airlines frequently announce orders, partnerships, and service deals.

Another key event looms: the U.S. employment report is set for Feb. 6. This comes after Thursday’s weekly jobless claims dropped by 4,000 to 209,000, according to a Reuters report.

GE Aerospace’s next key trigger will be any update that narrows the timeline on the GE9X durability testing. If that doesn’t come through, eyes will shift to order buzz from Singapore next week, followed by the February 6 payrolls report, which could shape the mood for industrial shares.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Snowflake stock slides nearly 8% in software rout; traders brace for next catalyst
Previous Story

Snowflake stock slides nearly 8% in software rout; traders brace for next catalyst

GSK share price dips in London as Exdensur rollout and Feb 4 results loom
Next Story

GSK share price dips in London as Exdensur rollout and Feb 4 results loom

Go toTop